Valbiotis SAS (France) Performance
| ALVAL Stock | EUR 1.39 0.02 1.46% |
Valbiotis SAS has a performance score of 2 on a scale of 0 to 100. The entity has a beta of -0.0396, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Valbiotis SAS are expected to decrease at a much lower rate. During the bear market, Valbiotis SAS is likely to outperform the market. Valbiotis SAS right now has a risk of 3.79%. Please validate Valbiotis SAS total risk alpha, expected short fall, price action indicator, as well as the relationship between the value at risk and daily balance of power , to decide if Valbiotis SAS will be following its existing price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Valbiotis SAS are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Valbiotis SAS may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
| Begin Period Cash Flow | 14.6 M | |
| Total Cashflows From Investing Activities | -7000.00 |
Valbiotis |
Valbiotis SAS Relative Risk vs. Return Landscape
If you would invest 133.00 in Valbiotis SAS on September 26, 2024 and sell it today you would earn a total of 6.00 from holding Valbiotis SAS or generate 4.51% return on investment over 90 days. Valbiotis SAS is generating 0.1362% of daily returns and assumes 3.7897% volatility on return distribution over the 90 days horizon. Simply put, 33% of stocks are less volatile than Valbiotis, and 98% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Valbiotis SAS Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Valbiotis SAS's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Valbiotis SAS, and traders can use it to determine the average amount a Valbiotis SAS's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0359
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | ALVAL | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.79 actual daily | 33 67% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average Valbiotis SAS is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Valbiotis SAS by adding it to a well-diversified portfolio.
Valbiotis SAS Fundamentals Growth
Valbiotis Stock prices reflect investors' perceptions of the future prospects and financial health of Valbiotis SAS, and Valbiotis SAS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Valbiotis Stock performance.
| Return On Equity | -0.72 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (12.72) % | |||
| Current Valuation | 35.17 M | |||
| Shares Outstanding | 12.41 M | |||
| Price To Book | 4.38 X | |||
| Price To Sales | 54.06 X | |||
| Revenue | 2.05 M | |||
| EBITDA | (7.51 M) | |||
| Cash And Equivalents | 541 K | |||
| Cash Per Share | 1.80 X | |||
| Total Debt | 6.13 M | |||
| Debt To Equity | 37.80 % | |||
| Book Value Per Share | 1.02 X | |||
| Cash Flow From Operations | (7.16 M) | |||
| Earnings Per Share | (1.07) X | |||
| Total Asset | 28.54 M | |||
About Valbiotis SAS Performance
Assessing Valbiotis SAS's fundamental ratios provides investors with valuable insights into Valbiotis SAS's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Valbiotis SAS is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Valbiotis SA develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients. Valbiotis SA was founded in 2014 and is based in Prigny, France. VALBIOTIS is traded on Paris Stock Exchange in France.Things to note about Valbiotis SAS performance evaluation
Checking the ongoing alerts about Valbiotis SAS for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Valbiotis SAS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Valbiotis SAS may become a speculative penny stock | |
| Valbiotis SAS had very high historical volatility over the last 90 days | |
| The company reported the revenue of 2.05 M. Net Loss for the year was (8.68 M) with profit before overhead, payroll, taxes, and interest of 298 K. | |
| Valbiotis SAS has accumulated about 541 K in cash with (7.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Valbiotis SAS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Valbiotis SAS's stock is overvalued or undervalued compared to its peers.
- Examining Valbiotis SAS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Valbiotis SAS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Valbiotis SAS's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Valbiotis SAS's stock. These opinions can provide insight into Valbiotis SAS's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Valbiotis Stock Analysis
When running Valbiotis SAS's price analysis, check to measure Valbiotis SAS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Valbiotis SAS is operating at the current time. Most of Valbiotis SAS's value examination focuses on studying past and present price action to predict the probability of Valbiotis SAS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Valbiotis SAS's price. Additionally, you may evaluate how the addition of Valbiotis SAS to your portfolios can decrease your overall portfolio volatility.